Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.31 USD | +2.21% | -4.48% | +42.54% |
May. 29 | TScan Therapeutics' Potential Blood Cancer Therapies Receive FDA Regenerative Medicine Status | MT |
May. 13 | Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target | MT |
Financials (USD)
Sales 2024 * | 7.01M | Sales 2025 * | 5.93M | Capitalization | 438M |
---|---|---|---|---|---|
Net income 2024 * | -131M | Net income 2025 * | -151M | EV / Sales 2024 * | 52.7 x |
Net cash position 2024 * | 68.9M | Net cash position 2025 * | 66.72M | EV / Sales 2025 * | 62.7 x |
P/E ratio 2024 * |
-6.74
x | P/E ratio 2025 * |
-6.28
x | Employees | 164 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.12% |
1 day | +1.59% | ||
1 week | -4.48% | ||
Current month | +7.64% | ||
1 month | +7.64% | ||
3 months | +15.42% | ||
6 months | +27.26% | ||
Current year | +42.54% |
Managers | Title | Age | Since |
---|---|---|---|
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Jason Amello
DFI | Director of Finance/CFO | 55 | Jan. 28 |
Justin McCue
CTO | Chief Tech/Sci/R&D Officer | - | Dec. 03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 76 | 19-02-28 | |
Stephen Biggar
BRD | Director/Board Member | 53 | 21-02-28 |
Gavin MacBeath
CEO | Chief Executive Officer | 54 | 18-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-30 | 8.29 | +1.34% | 195,270 |
24-05-29 | 8.18 | -6.41% | 274,341 |
24-05-28 | 8.74 | +3.92% | 260,831 |
24-05-24 | 8.41 | -3.33% | 220,362 |
24-05-23 | 8.7 | -8.52% | 122,477 |
Delayed Quote Nasdaq, May 30, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+42.54% | 438M | |
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+38.14% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |
- Stock Market
- Equities
- TCRX Stock